AMIX — Autonomix Medical Inc · catalysts, narrative & risks

As of 2026‑07‑30, Autonomix Medical Inc. (ticker AMIX) has emerged as a key player in the precision nerve‑targeted medical device sector, with a robust pipeline that spans pain management, hypertension, and other nerve‑related conditions [1]. The company’s recent catalysts—centered on its warrant inducement agreement, clinical conference presentations, and upcoming shareholder events—have positioned AMIX for a potential 12‑month price target between $42.00 and $58.82, translating into an upside potential of roughly 1,400 % from the last trade [1][3][7].